Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Tax Provisions (2024 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Tax Provisions for 5 consecutive years, with -$1.0 million as the latest value for Q4 2025.

  • For Q4 2025, Tax Provisions rose 88.55% year-over-year to -$1.0 million; the TTM value through Dec 2025 reached $43.2 million, down 2.3%, while the annual FY2025 figure was -$1.0 million, 102.3% down from the prior year.
  • Tax Provisions hit -$1.0 million in Q4 2025 for Agios Pharmaceuticals, up from -$8.9 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $53.1 million in Q3 2024 and bottomed at -$8.9 million in Q4 2024.